GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » Price-to-Free-Cash-Flow

Arvinas (Arvinas) Price-to-Free-Cash-Flow : N/A (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arvinas Price-to-Free-Cash-Flow?

As of today (2024-05-23), Arvinas's share price is $35.23. Arvinas's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.98. Hence, Arvinas's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Arvinas's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 8 years, Arvinas's highest Price-to-Free-Cash-Flow Ratio was 155.93. The lowest was 3.53. And the median was 6.17.

ARVN's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.86
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Arvinas's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-1.36. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-5.98.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -37.50% per year.

During the past 8 years, Arvinas's highest 3-Year average Free Cash Flow per Share Growth Rate was -9.00% per year. The lowest was -54.60% per year. And the median was -37.50% per year.


Arvinas Price-to-Free-Cash-Flow Historical Data

The historical data trend for Arvinas's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arvinas Price-to-Free-Cash-Flow Chart

Arvinas Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - 7.40 - -

Arvinas Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arvinas's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Arvinas's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arvinas's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arvinas's Price-to-Free-Cash-Flow falls into.



Arvinas Price-to-Free-Cash-Flow Calculation

Arvinas's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=35.23/-5.98
=N/A

Arvinas's Share Price of today is $35.23.
Arvinas's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.98.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Arvinas  (NAS:ARVN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Arvinas Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Arvinas's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Arvinas (Arvinas) Business Description

Traded in Other Exchanges
N/A
Address
395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Executives
Ronald Peck officer: Chief Medical Officer C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal director 60 LEVERONI COURT, NOVATO CA 94949
Ian Taylor officer: Senior Vice President, Biology C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston director, officer: President and CEO C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy officer: Chief Financial Officer 322 EAST MAIN STREET, BRANFORD CT 06405
Everett Cunningham director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
David K Loomis officer: Chief Accounting Officer C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
John D Young director C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe director, 10 percent owner C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon director C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr. director C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon director
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139